组织工程骨的再血管化研究

Revascularization of tissue engineered bone

目的:探讨组织工程骨再血管化的方法及其应用效果和前景。资料来源:应用计算机检索Medline1980-01/2004-06期间组织工程骨再血管化方面的相关文章,检索词“Tissueengineeredbone;Revascular-ization”,并限定文章语言种类为English。同时计算机检索清华同方数据库2000-01/2004-06期间相关文章,限定文章语言种类为中文,检索词“组织工程骨,再血管化”。资料选择:资料纳入标准①组织工程骨再血管化方法和对照之间的比较研究。②组织工程骨再血管化方法之间的比较研究。资料提炼:共检索到组织工程骨再血管化方面的相关文献31篇,筛除明显不随机试验研究和重复研究8篇,共有23篇文章符合纳入标准。其中有2篇为关于松质骨和羟基磷灰石三维孔隙结构的研究,2篇为在支架材料中种植细胞密度的研究,6篇为在支架材料中复合生长因子的研究,5篇为血管内皮细胞与成骨细胞联合培养方面的研究,2篇为在组织工程骨中植入血管束的研究,3篇为用筋膜包被组织工程骨的研究,3篇为预构组织工程骨的研究。资料综合:支架材料适宜的三维孔隙结构、在支架材料上以适宜的密度种植种子细胞、在细胞和支架材料复合物中复合适量的生长因子、血管内皮细胞与成骨细胞以适宜的比例联合培养后与支架材料复合移植、将血管束植入组织工程骨、用筋膜瓣包裹组织工程骨及将组织工程骨预先置于各种带蒂肌瓣中预构均有利于组织工程骨的再血管化。预构组织工程骨是在异位完成血管化,不受骨缺损局部条件的影响,其临床应用前景可观。结论:将组织工程骨置于体内血液供应良好的带蒂组织内预构,是在异位完成组织工程骨的再血管化,形成具有血运的组织工程骨,然后行带蒂或吻合血管的组织工程骨移植修复骨缺损,不受骨缺损局部血液供应条件的影响,理论上可明显提高组织工程骨的成活率和修复骨缺损的成功率。

OBJECTIVE： To investigate the methods of revascularization of tissue engineered bone, and study its applied results and its prospect. DATA SOURCES： A computer-hased search of Medline database was undertaken to identify articles about revascularization of tissue engineered bone published in English between January 1980 and July 2004 by using the keywords of “tissue engineered bone, revascularization”. Chinese relevant articles published between January 2000 and June 2004 were searched in China National Knowledge Infrastructure （CNKI） with the keywords of “tissue engineered bone, revascularization”. STUDY SELECTION： Inclusive criteria：① comparison of the method of revascularization of tissue engineered bone with controls;②comparison of the different methods of revascularization of tissue engineered bone. DATA EXTRACTION： Totally 31 articles about the revascularization of tissue engineered bone were collected, 8 obvious non-randomized trials and repetitive studies were screened, and 23 articles accorded with the inclusive criteria, including 2 articles about study on cancellous bone and 3-dimension pore of hydroxyapatite ceramic, 2 about cell density planted in scaffold materials, 6 about scaffold materials compound cell growth factor, 5 about co-cuhivation with vascular endothelial cell and sclerotomal cell, 2 about vascular bundle planted in scaffolds, 3 about tissue engineered bone coating with anadesma, 3 about pretreatment of tissue engineered bone DATA SYNTHESIS： The appropriate 3-dimension pore of scaffold materials, quantity sufficien cell density planted and compound cell growth factor, planted after co-cultivation with vascular endothelial cell and sclerotomal cell, tissue engineered bone planted with vascular bundle, coating with anadesma and pretreated in pedicle muscle flap were all benefits to the revascularization of tissue engineered bone. But, pretreatment of tissue engineered bone was revascularization completed in other place and it was not effected by the condition of bone coloboma.lts clinical application foreground is considerable CONCLUSION： It was revascularization completed in other place that tissue engineered bone changed to bone with blood circulation pretreated in pedicle tissue flap. By using it to repair bone coloboma is not affected by the partial blood circulation of bone coloboma. Theoretically, it can obviously increase the survival rate with tissue engineered bone and achievement ratio with repairing bone coloboma.